The PennZone

  • Home
  • Non-profit
  • Health
  • Books
  • Business
  • Entertainment
  • Legal
  • Marketing
  • Sports

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • New Bethany, Provident Bank, Jaindl Farms and Lehigh Valley IronPigs Unite for Turkey Drive
  • Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • 6,238 executives took new roles at US nonprofits from June to October 2026
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Minneapolis
  • LGF Lab Gas Flow Launches Fully Automatic Laboratory Gas Changeover Manifold System with Ultra High Purity Gas Regulator Valve
  • Woodside Village Joins Corner Property Management Following CMP Acquisition
  • 20-Year Crash Cost of Signalized RC3 Cloverleaf Could Exceed $25 Million

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Angela's Boutique Highlights Self-Care Gifts for Philadelphia Holiday Shoppers
  • Turkish Engineer Who Cracked Wall Street's Algorithm Launches Hermes AI Analyzer
  • UK Financial Ltd Launches MayaSwap On MAYA CHAIN To Facilitate UKFLMS-For-Gold Swaps, Officially Transforming UKFLMS From Meme Into A Real-World Asset
  • Entrepreneur Nouho M Kanneh Talks Family, Faith and a $37 Million Portfolio in New Interview
  • Emerald Williams Selected to Super Lawyers Rising Stars 2022-2026
  • Massive Acquisition Into Defense With STS for Virtuix Holdings; $40 Million Revenue Business Will Accelerate Growth Transforming Market Position
  • Orlando Real Estate Broker Bent Danholm Wins 2026 Goody Business Book Award for The Architecture of Demand
  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • The King Returns: Satirical December 2026 Rematch Sees Challenger Delayed by a Christmas Light Installation
  • Veteran Antiques Expert John Swahn Releases New Book: The Truth About Antiques
  • Steven Weisz of Art Imagined Photography to exhibit at ExpoMetro Florence, Italy
  • Hope Survives Managing Director Jasmine Balignasay-Chavez Receives 2026 Catalyst Award
  • LCH2 Awarded Additional $1 Million to Advance Lewis County Clean Energy Campus
  • Security Planning Tips For Your Holiday Event From Access Patrol Services
  • Kellyn Co-Founder Meagan Grega Named President-Elect of the American College of Lifestyle Medicine
  • Contracting Resources Group Receives 2026 HIRE Vets Platinum Medallion Award
  • Business News & Info Goes Inside Paragon FX Group's Hunt for Original Film Props
  • Kitchen Table Economics: An Invitation to Think Differently
  • New Bethany, Provident Bank, Jaindl Farms and Lehigh Valley IronPigs Unite for Turkey Drive
  • Grace Montessori School Awarded $56,180 to Support Scholarships for 15 Students

Popular on PennZone

  • ASSIST Software Wins Volkswagen Challenge for Automated Quality Inspection - 177
  • ALight Technology And Services Limited Advances Through Peachscore + Dealum Accelerator and Join LvlUp Labs - 166
  • Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal - 161
  • What Mold Remediation Costs in Gettysburg, PA: 2026 Price Ranges by Job Type - 154
  • New Children's Picture Book "Adam's Apple" Celebrates Childhood Curiosity and the Funny Misundersta - 138
  • New Children's Picture Book "Tippy Tay" Explores the Dangers of Peer Pressure and the Importance of - 135
  • WebDrafter Welcomes Dreamwork Exteriors as a New Marketing Client - 131
  • Sycamore Dove Releases "Loving Every Moment" - 120
  • Conservative Latinos for PA PAC Endorses Stacy Garrity for Governor: "Pennsylvania's Latino Families Need a Leader Who Delivers" - 107
  • Communities In Schools of Eastern Pennsylvania Honors United Way and Local Leaders

Similar on PennZone

  • Commercial Sales for U.S.-Made, Preservative-Free Ketamine Amid Long-Runnin Shortage Following FDA Approval by NRx Pharmaceuticals, Inc
  • TCA VG: 2025 Funding Climbs to $9M across 43 Companies; Cumulative Returns Reach 5.3 MOIC & 22% IRR
  • Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
  • OncoBeta Introduces Rhenium-SCT for Non-Melanoma Skin Cancer at Theageneio Cancer Hospital of Thessaloniki
  • New Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, Inc
  • New TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, Inc
  • FDA Approval; Major Milestone for Preservative-Free Ketamine Ahead of FDA Goal Date for Treatment of Suicidal Depression by NRx Pharmaceuticals, Inc
  • Major FDA Victory; Preservative-Free Ketamine Approved Ahead of November 10 Goal Date as Commercial Launch Opportunity Comes Into Focus for NRx Pharma
  • New Research Spotlight, Expanding TUSC2 Science & Strategic Development Milestones Put Gene Therapy Innovation into Focus for Genprex (NAS DAQ: GNPX)
  • Expanding Into Medically Supervised Wellness With Major Apollo Wellness Centers Announcement; Sibannac, Inc. (Stock Symbol: SNNC)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us